NCT07318649 2026-01-06
Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation
Suzhou Genhouse Bio Co., Ltd.
Phase 2 Not yet recruiting